博迅生物
(920504)
| 流通市值：3.10亿 | | | 总市值：7.86亿 |
| 流通股本：1709.19万 | | | 总股本：4333.31万 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 59,246,977.51 | 26,599,005.35 | 119,810,751.55 | 84,576,132.64 |
| 营业收入 | 59,246,977.51 | 26,599,005.35 | 119,810,751.55 | 84,576,132.64 |
| 二、营业总成本 | 52,386,955.98 | 24,273,581.88 | 107,019,235.22 | 75,863,313.61 |
| 营业成本 | 35,796,508.28 | 16,097,142.76 | 70,355,781.71 | 49,787,907.73 |
| 税金及附加 | 429,005.35 | 128,593.39 | 1,044,948.06 | 625,309.39 |
| 销售费用 | 4,760,331.18 | 2,288,189.25 | 10,037,521.13 | 7,810,883.29 |
| 管理费用 | 8,842,928.29 | 4,464,624.57 | 18,999,484.78 | 13,573,921.53 |
| 研发费用 | 2,491,780.13 | 1,239,647.87 | 6,633,267.31 | 4,107,770.22 |
| 财务费用 | 66,402.75 | 55,384.04 | -51,767.77 | -42,478.55 |
| 其中:利息费用 | 266,237.48 | 132,563.84 | 642,856.4 | 492,994.57 |
| 其中:利息收入 | 243,078.19 | 110,115.43 | 734,146.75 | 560,110.78 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 134,328.19 | 85,249.53 | 219,671.24 | 154,375.98 |
| 加:投资收益 | 617,957.89 | 190,844.28 | 1,430,454.32 | 1,072,669.19 |
| 资产处置收益 | - | - | 69,294.85 | 9,124.34 |
| 资产减值损失(新) | -617,167.84 | -288,697.6 | -2,165,944.77 | -1,728,199.67 |
| 信用减值损失(新) | -972,724.21 | -838,744.58 | -21,911.09 | -1,065,234.82 |
| 其他收益 | 1,657,019.76 | 268,564.81 | 4,424,267.98 | 2,910,811.68 |
| 四、营业利润 | 7,679,435.32 | 1,742,639.91 | 16,747,348.86 | 10,066,365.73 |
| 加:营业外收入 | 343.11 | 343.11 | 65,331.98 | 77,539.56 |
| 减:营业外支出 | 106.95 | 106.95 | 476,435.26 | 475,433.9 |
| 五、利润总额 | 7,679,671.48 | 1,742,876.07 | 16,336,245.58 | 9,668,471.39 |
| 减:所得税费用 | 773,436.33 | 247,254.06 | 1,421,541.44 | 1,124,707.44 |
| 六、净利润 | 6,906,235.15 | 1,495,622.01 | 14,914,704.14 | 8,543,763.95 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 6,906,235.15 | 1,495,622.01 | 14,914,704.14 | 8,543,763.95 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 6,906,235.15 | 1,495,622.01 | 14,914,704.14 | 8,543,763.95 |
| 扣除非经常损益后的净利润 | 5,828,413.03 | 1,264,434.43 | 12,664,509.33 | 6,978,648.29 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.16 | 0.03 | 0.34 | 0.2 |
| (二)稀释每股收益 | 0.16 | 0.03 | 0.34 | 0.2 |
| 九、综合收益总额 | 6,906,235.15 | 1,495,622.01 | 14,914,704.14 | 8,543,763.95 |
| 归属于母公司股东的综合收益总额 | 6,906,235.15 | 1,495,622.01 | 14,914,704.14 | 8,543,763.95 |
| 公告日期 | 2026-08-25 | 2026-04-28 | 2026-03-30 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |